Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed
Recent Adv Inflamm Allergy Drug Discov
.
2023;17(2):85-87.
doi: 10.2174/2772270817666230320153734.
Authors
George N Konstantinou
1
,
Maria Petrodimopoulou
1
Affiliation
1
Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.
PMID:
36959139
DOI:
10.2174/2772270817666230320153734
No abstract available
Publication types
Editorial
MeSH terms
Allergens / therapeutic use
Biological Products* / therapeutic use
Cost-Benefit Analysis
Immunotherapy
Substances
Biological Products
Allergens